Cyclosporine: Update on pharmacology, analytical techniques and therapeutic monitoring

Bollettino Chimico Farmaceutico

Volumn 136, Issue 9, 1997, Pages 577-588

  Santori, L ^a   Rastelli, M ^a   Arena, B ^b   Morleo, M A ^a  

^a Ospedale Civile   (Italy)

^b Servizio Materno Infantile   (Italy)

Author keywords

Cyclosporine; HPLC methods; Immunological methods; Metabolites; Therapeutic monitoring

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ANIMAL; HUMAN; REVIEW;

ANIMALS; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 0031243689     PISSN: 00066648     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Shaw LM, Bowers L, Demers L, et al: «Critical Issues in Cyclosporine Monitoring» Report of the Task Force on Cyclosporine Monitoring. Clin. Chem. 33 (7), 1269-1288 (1987).
2. Kahan BD: Cyclosporine. N Engl J Med 321, 1725-1737 (1989).
3. Shaw LM: Advances in cyclosporine pharmacology, measurement and therapeutic monitoring. Clin Chem 35, 1299-1308 (1989).
4. Koletsky AJ, Harding MW, Handschumacher RE: Cyclophilin: distribution and variant properties in normal and neoplastic tissues. J. Immunol 137, 1054-1059 (1986).
5. Fischer G, Wittmann-Liebold B, Lang K, Kiefhaber T, Schmid FX: Cyclophilin and peptydyl-prolyl cis-trans isomerase are probably identical proteins. Nature 337, 476-478 (1989).
6. Takahashi N, Haiano T, Masanori S: Peptydyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature 337, 473-475 (1989).
7. Tocci MJ, Matkovich DA, Collier KA, Kwok P, Dumont F, Lin S, Degudicibus S, Siekierka JJ, Chin J, Hutchinson NI: The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol. 143, 718-726 (1989).
8. Todo S, Demetris A, Ueda Y, Mventarza O, Cadoff E, Zeevi A. Starzl TE: Renal transplantation in baboons under FK506. Surgery 106, 444-451 (1989).
9. Goodman Gilman A, Rail TW, Nies AS, Taylor P Goodman § Gilman's «The pharmacological basis of therapeutics». Pergamon Press (1991).
10. Lindholm A: Factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monit 13, 6 465-477 (1991).
11. Gerson B.: Cyclosporine controversies. Clin Lab Med 7, 669-685 (1987).
12. Consensus document: Hawk's Cay Meeting on therapeutic drug monitoring of Cyclosporine. Transplant Proc 22, 1357-1361 (1990).
13. Maurer G, Lemaire M: Biotransformation and distribution in blood of cyclosporine and its metabolites. Transplant Proc 18, 6 (suppl 5) 25-30 (1986).
14. Freed BM, Rosano TG, Cerilli J, Lempert N: In vitro immunosuppressive properties of cyclosporine metabolites. Transplantation 43, 123-127 (1987).
15. Zeevi A, Eiras G, Burckart G, et al.: Immunosuppressive effect of cyclosporine metabolites from human bile on alloreactive T cells. Transplant Proc 20 (Suppl 2), 115-121 (1988).
16. Yatscoff RW, Copeland KR, Faraci CJ: Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood. Clin Chem 36, 1969-1973 (1990).
17. Kolbeck PC, Scheinman JI, Sanfilippo F: Acute cellular rejection and cyclosporine nephrotoxicity monitored by biopsy in a renal allograft rejection. Arch Pathol Lab Med 110, 389-393 (1986).
18. Lensmeyer GL, Wiebe DA, Carlson IH: Distribution of cyclosporin A metabolites among plasma and cells in whole blood: effect of temperature, hematocrit, and metabolites concentration. Clin Chem 35(1), 56-63 (1989).
19. Lindholm A, Henricsson S: Intra- and interindividual variability in the free fraction of cyclosporine in plasma in recipients of renal transplant. Ther Drug Monit 11(6), 623-630 (1989).
20. Plebani M, Paleari CD, Burlina A: La ciclosporina: meccanismi d'azione e problemi analitici nel monitoraggio terapeutico. Progr Med Lab 4(2), 67-80 (1990).
21. Annesley T, Matz K, Bologh L, Clayton L, Giachesio D: Liquid chromatographic analysis for cyclosporine with use of a microbore column and small sample volume. Clin Chem 32, 1407-1409 (1986).
22. Kabra PM, Wall JH, Dimson P: Automated solid phase extraction and liquid chromatography for assay of cyclosporine in whole blood. Clin Chem 33, 2272-2274 (1987).
23. Plebani M, Masiero M, Paleari CD, Sciacovelli L, Faggian D, Burlina A: High performance liquid chromatography for cyclosporin measurement: comparison with radioimmunoassay. J Chromatogr 1989; 476: 93-98.
24. Lensmeyer GL, Fields BL: Improved liquid chromatographic determination of cyclosporine, with concomitant determination of a cell-bound metabolite. Clin Chem 1985; 31: 196-201.
25. Lensmeyer GL, Wiebe DA, Carlson IH: Identification and analysis of nine metabolites of cyclosporine in whole blood by liquid chromatography. Purification of analytical standards and optimization of the assay. Clin Chem 33(10), 1841-1850 (1987).
26. Holman JW, Felder RA: Robotic automation of cyclosporine analysis in whole blood. Clin Chem 38(8), 1440-1443 (1992).
27. Donnelly JG, Soldin SJ: A radioreceptor assay for the measurement of cyclosporine activity: a preliminary report. Ther Drug Monit 11, 696-700 (1989).
28. Soldin SJ: Receptor assay in the Clinical Laboratory. Clin Biochem 29: 439-444 (1996).
29. Soldin SJ: Receptor (Immunophilin-Binding) assay for immunosuppressive drugs. Ther Drug Monit 17: 574-576 (1995).
30. Copeland KR, Yatscoff RW, McKenna RM: Immunosuppressive activity of cyclosporine metabolites compared and characterized by mass spectroscopy and nuclear magnetic resonance. Clin Chem 36, 225-229 (1990).
31. Morris RG, Saccoia NC, Ryall RG, Peacock MK, Sallustio BC: Specific enzyme-multiplied immunoassay and fluorescence polarization immunoassay for cyclosporin compared with Cyclotrac 125 I Radioimmunoassay. Ther Drug Monit 14, 226-233 (1992).
32. Kivisto KT: Misleading use of correlation and regression in method-comparison studies of cyclosporine. Clin Chem 39, 167-168 (1993).
33. Jones PM, Brune K: Monitoring cyclosporine by HPLC with cyclosporin C as internal standard. Clin Chem 39, 168-169 (1993).
34. Tredger JM, Gonde CE, Williams R: Monitoring cyclosporine in liver-transplant recipients. Clin Chem 39, 164-165 (1993).
35. Shearing CH: A specific radioimmunoassay for cyclosporine? Clin Chem 36, 1853-1855 (1990).
36. Oellerich M. et al.: Lake Louise Consensus Conference on Cyclosporin monitoring in organ transplantation: Report of the Consensus Panel. Ther Drug Monitor 17, 642-654 (1995).
37. Copeland KR, Yatscoff RW: The isolation, structural characterization and immunosuppressive activity of cyclosporin G(NVa2-Cyclosporine) metabolites. Ther Drug Monitor 13, 281-288 (1991).
38. Annesley TM, Matz K, Leichtman AB: High-Performance Liquid Chromatographic analysis of Cyclosporin G (Nva2 -Cyclosporine) in human blood. Ther Drug Monitor 14, 397-401 (1992).
39. Donnelly JG, Chen Y, Yatscoff RW, Copeland KR, Palaszynski EW, Soldin SJ: Cyclosporin G and metabolite binding to cyclophilin and a 50-kDa protein related to in vitro immunosuppression. Clin Chem 39(1), 122-125 (1993).
40. Annesley TM, Coombs RC, Orsulak PJ: Comparison of Cyclosporin G (Nva2-Cyclosporin) concentrations measured in whole blood by monoclonal fluorescence polarization immunoassay, monoclonal radioimmunoassay and HPLC. Clin Chem 39, 1050-1053 (1993).
41. Yatscoff RW, Langman LJ, LeGatt DF: Cross-reactivities of Cyclosporin G (NVa2-Cyclosporin) and metabolites in Cyclosporin A immunoassays. Clin Chem 39, 1089-1092 (1993).